Charles Schwab Investment Management Inc Zentalis Pharmaceuticals, Inc. Transaction History
Charles Schwab Investment Management Inc
- $557 Billion
- Q2 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 299,097 shares of ZNTL stock, worth $463,600. This represents 0.0% of its overall portfolio holdings.
Number of Shares
299,097
Previous 486,499
38.52%
Holding current value
$463,600
Previous $773,000
55.24%
% of portfolio
0.0%
Previous 0.0%
Shares
22 transactions
Others Institutions Holding ZNTL
# of Institutions
123Shares Held
60.6MCall Options Held
0Put Options Held
22K-
Matrix Capital Management Company, LP Waltham, MA14MShares$21.6 Million8.42% of portfolio
-
Black Rock Inc. New York, NY4.82MShares$7.47 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.48MShares$5.39 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.88MShares$4.47 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA2.8MShares$4.34 Million0.01% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $88.3M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...